Long Noncoding RNAs As Novel Serum Biomarkers For The Diagnosis Of Hepatocellular Carcinoma:a Systematic Review And Meta-analysis

Objective:To investigate the clinical value of long non-coding RNA(lncRNA)in the clinical diagnosis of hepatocellular carcinoma(HCC),and to review the progress of lncRNA and hepatocellular carcinoma.Methods:1.to retrieve the English literatures related to lncRNA and liver cancer diagnosis in Pubmed,Embase and other databases.2.After carefully reading the literature,the true positive rate(TP),false positive rate(FP),true negative rate(TN)and false negative rate(FN)were extracted.3.The sensitivity,specificity,positive likelihood ratio(PLR),negative likelihood ratio(NLR)and diagnostic odds ratio were obtained by meta-disc,STATA14 and Revman5.3 software.4.The above effects were calculated and the area under the curve(AUC)of the receiver operating characteristic(sROC)curve was calculated to evaluate the total accuracy.Results:Ten studies with a total of 820 HCC patients and 785 healthy controls were included.For overall lncRNAs,the pooled sensitivity,specificity,and DOR to predict HCC patients were 80% [95% confidence interval(CI)77–82%],79%(95% CI76–81%),and 27.66(95% CI 14.26–53.63),respectively,corresponding to an AUC of0.91.Conclusions:Lnc RNAs were a high diagnostic value for HCC and its expression couldpotentially be used as auxiliary biomarker in confirming HCC.